Literature DB >> 14567626

Drug delivery and transport to solid tumors.

Seong Hoon Jang1, M Guillaume Wientjes, Dan Lu, Jessie L S Au.   

Abstract

PURPOSE: The purpose of this review is to provide an overview of the principles of and barriers to drug transport and delivery to solid tumors.
METHODS: This review consists of four parts. Part I provides an overview of the differences in the vasculature in normal and tumor tissues, and the relationship between tumor vasculature and drug transport. Part II describes the determinants of transport of drugs and particles across tumor vasculature into surrounding tumor tissues. Part III discusses the determinants and barriers of drug transport, accumulation, and retention in tumors. Part IV summarizes the experimental approaches used to enhance drug delivery and transport in solid tumors.
RESULTS: Drug delivery to solid tumors consists of multiple processes, including transport via blood vessels, transvascular transport, and transport through interstitial spaces. These processes are dynamic and change with time and tumor properties and are affected by multiple physicochemical factors of a drug, multiple tumor biologic factors, and as a consequence of drug treatments. The biologic factors, in turn, have opposing effects on one or more processes in the delivery of drugs to solid tumors.
CONCLUSION: The effectiveness of cancer therapy depends in part on adequate delivery of the therapeutic agents to tumor cells. A better understanding of the processes and contribution of these factors governing drug delivery may lead to new cancer therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14567626     DOI: 10.1023/a:1025785505977

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  149 in total

Review 1.  Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention.

Authors:  F M Muggia
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

Review 2.  Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis.

Authors:  A Saaristo; T Karpanen; K Alitalo
Journal:  Oncogene       Date:  2000-12-11       Impact factor: 9.867

3.  Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

Authors:  Maurie Markman; James Hall; Daniel Spitz; Sheldon Weiner; Linda Carson; Linda Van Le; Mark Baker
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

4.  Combination radioimmunotherapy with local hyperthermia: increased delivery of radioimmunoconjugate by vascular effect and its retention by increased antigen expression in colon cancer xenografts.

Authors:  S Kinuya; K Yokoyama; T Hiramatsu; H Tega; K Tanaka; S Konishi; N Shuke; T Aburano; N Watanabe; T Takayama; T Michigishi; N Tonami
Journal:  Cancer Lett       Date:  1999-06-01       Impact factor: 8.679

5.  Host--tumour relationship. XX. The hexosamine content of the tumour as a marker of relations between the tumour stroma and tumour cells.

Authors:  Z Brada
Journal:  Neoplasma       Date:  1965       Impact factor: 2.575

6.  Microcirculatory studies in rat mammary carcinoma. I. Transparent chamber method, development of microvasculature, and pressures in tumor vessels.

Authors:  W Peters; M Teixeira; M Intaglietta; J F Gross
Journal:  J Natl Cancer Inst       Date:  1980-09       Impact factor: 13.506

7.  Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol.

Authors:  L Milas; N R Hunter; B Kurdoglu; K A Mason; R E Meyn; L C Stephens; L J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse.

Authors:  Y Boucher; R K Jain
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

9.  Pharmacodynamics of taxol in human head and neck tumors.

Authors:  Y Gan; M G Wientjes; D E Schuller; J L Au
Journal:  Cancer Res       Date:  1996-05-01       Impact factor: 12.701

10.  Hyperthermia enhances localization of 111In-labeled hapten to bifunctional antibody in human colon tumor xenografts.

Authors:  D S Gridley; K L Ewart; J D Cao; D R Stickney
Journal:  Cancer Res       Date:  1991-03-01       Impact factor: 12.701

View more
  121 in total

1.  Effect of wall compliance and permeability on blood-flow rate in counter-current microvessels formed from anastomosis during tumor-induced angiogenesis.

Authors:  Peng Guo; Bingmei M Fu
Journal:  J Biomech Eng       Date:  2012-04       Impact factor: 2.097

Review 2.  Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming.

Authors:  Jie Wang; Ze Lu; Yue Gao; M Guillaume Wientjes; Jessie L-S Au
Journal:  Nanomedicine (Lond)       Date:  2011-11       Impact factor: 5.307

Review 3.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

Review 4.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

5.  A ceramic-based anticancer drug delivery system to treat breast cancer.

Authors:  Ahmed El-Ghannam; Krista Ricci; Ahmed Malkawi; Kiarash Jahed; Kumar Vedantham; Heather Wyan; Lauren D Allen; Didier Dréau
Journal:  J Mater Sci Mater Med       Date:  2010-07-20       Impact factor: 3.896

6.  Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.

Authors:  Jie Wang; Ze Lu; Junfeng Wang; Minjian Cui; Bertrand Z Yeung; David J Cole; M Guillaume Wientjes; Jessie L-S Au
Journal:  J Control Release       Date:  2015-08-10       Impact factor: 9.776

Review 7.  Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.

Authors:  Jessie L-S Au; Bertrand Z Yeung; Michael G Wientjes; Ze Lu; M Guillaume Wientjes
Journal:  Adv Drug Deliv Rev       Date:  2015-12-11       Impact factor: 15.470

8.  Albumin-binding and tumor vasculature determine the antitumor effect of 15-deoxy-Delta-(12,14)-prostaglandin-J(2) in vivo.

Authors:  Jai Prakash; Ruchi Bansal; Eduard Post; Alie de Jager-Krikken; Marjolijn N Lub-de Hooge; Klaas Poelstra
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

9.  Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity.

Authors:  Krystyna M Wozniak; James J Vornov; Ying Wu; Kenichi Nomoto; Bruce A Littlefield; Christopher DesJardins; Yanke Yu; George Lai; Larisa Reyderman; Nancy Wong; Barbara S Slusher
Journal:  Cancer Res       Date:  2016-04-13       Impact factor: 12.701

Review 10.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.